Compare XPOF & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | SIGA |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.6M | 223.8M |
| IPO Year | 2021 | 2016 |
| Metric | XPOF | SIGA |
|---|---|---|
| Price | $4.92 | $2.98 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.13 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 780.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ 35.24 | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $11,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.63 | $224.81 |
| P/E Ratio | ★ N/A | $22.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.83 | $2.83 |
| 52 Week High | $9.39 | $9.45 |
| Indicator | XPOF | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 27.86 | 34.55 |
| Support Level | $4.50 | N/A |
| Resistance Level | $6.15 | $4.84 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 14.43 | 24.17 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.